Unknown

Dataset Information

0

Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.


ABSTRACT:

Background

Prophylactic cotrimoxazole is recommended for infants born to HIV-infected mothers. However, cotrimoxazole may increase the risk of severe anemia or neutropenia.

Methods

We compared the proportion of HIV-exposed uninfected (HIV-EU) infants experiencing incident severe anemia (and separately, severe neutropenia) between a prospective cohort receiving prophylactic cotrimoxazole from 1 to 6 months vs. infants from two prior trials who did not receive cotrimoxazole. Infants were from rural and urban communities in southern Botswana.

Results

A total of 1705 HIV-EU infants were included. Among these 645 (37.8%) were fed with iron-supplemented formula from birth. Severe anemia developed in 87 (5.1%) infants, and severe neutropenia in 164 (9.6%) infants. In an analysis stratified by infant feeding method, there were no significant differences in the risk of severe anemia by prophylactic cotrimoxazole exposure-risk difference, -0.69% (95% confidence interval [CI] -2.1 to 0.76%). Findings were similar in multivariable analysis, adjusted odds ratio (aOR) 0.35 (95% CI 0.07 to 1.65). There were also no significant differences observed for severe neutropenia by cotrimoxazole exposure, risk difference 2.0% (95% CI -1.3 to 5.2%) and aOR 0.80 (95% CI 0.33 to 1.93).

Conclusions

Severe anemia and severe neutropenia were infrequent among HIV-exposed uninfected infants receiving cotrimoxazole from 1-6 months of age. Concerns regarding hematologic toxicity should not limit the use of prophylactic cotrimoxazole in HIV-exposed uninfected infants. CLINICALTRIAL.SGOV REGISTRATION NUMBERS: NCT01086878 (http://clinicaltrials.gov/show/NCT01086878), NCT00197587 (http://clinicaltrials.gov/show/NCT00197587), and NCT00270296 (http://clinicaltrials.gov/show/NCT00270296).

SUBMITTER: Dryden-Peterson S 

PROVIDER: S-EPMC3781096 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.

Dryden-Peterson Scott S   Jayeoba Oluwemimo O   Hughes Michael D MD   Jibril Haruna H   McIntosh Kenneth K   Modise Taolo A TA   Asmelash Aida A   Powis Kathleen M KM   Essex Max M   Shapiro Roger L RL   Lockman Shahin S  

PloS one 20130923 9


<h4>Background</h4>Prophylactic cotrimoxazole is recommended for infants born to HIV-infected mothers. However, cotrimoxazole may increase the risk of severe anemia or neutropenia.<h4>Methods</h4>We compared the proportion of HIV-exposed uninfected (HIV-EU) infants experiencing incident severe anemia (and separately, severe neutropenia) between a prospective cohort receiving prophylactic cotrimoxazole from 1 to 6 months vs. infants from two prior trials who did not receive cotrimoxazole. Infants  ...[more]

Similar Datasets

| S-EPMC3356697 | biostudies-literature
| S-EPMC6059368 | biostudies-literature
| S-EPMC4540431 | biostudies-literature
| S-EPMC7190205 | biostudies-literature
| S-EPMC5810322 | biostudies-literature
| S-EPMC7778358 | biostudies-literature
| S-EPMC4146715 | biostudies-literature
| S-EPMC5403425 | biostudies-literature
| S-EPMC6785676 | biostudies-literature
| S-EPMC7988866 | biostudies-literature